Overview

Asthma Exacerbation Study

Status:
Completed

Trial end date:
2011-09-15

Target enrollment:

Participant gender:

Summary

This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fluticasone
Xhance